OCRA's New Initiatives for 2023
OCRA's New Initiatives for 2023
Please give today to stand with patients, fund lifesaving breakthroughs, and bring us closer to a cure: https://ocrahope.org/donatetodayIn 2023, OCRA will launch several initiatives that will deepen our mission and help us provide the best possible support for everyone impacted by ovarian cancer -- and we need your support.
In the coming year, OCRA will launch a free genetic testing program for people at risk for ovarian cancer, including first-degree relatives of those diagnosed; break new ground by expanding our scope to include related gynecologic cancers; create a patient registry, and a centralized data sharing system among leading cancer institutions focused on rare ovarian cancers; grow our patient support programs, and establish a patient fund to help ease financial burden for patients.
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.